• N&PD Moderators: Skorpio

Dimemorfan

monstanoodle

Bluelight Crew
Joined
Aug 13, 2007
Messages
10,909
Location
T'Norf
buh?

Read it is a cough suppressant on wiki. but it tells me balls all else about it.

from the systematic name , (9α,13α,14α)-3,17-dimethylmorphinan, it's obviously in the opioid family maybe semi synthetic.

but anyone else know any other worthwhile info?

(and no, i am not trying to get high off it just curiosity)
 
It seems to be DXM with the methoxy replaced by a methyl group. Here are a couple of references on its effects:
http://www.nature.com/bjp/journal/v144/n7/abs/0705998a.html
http://www.nature.com/bjp/journal/v138/n5/abs/0705117a.html

Seems to be a sigma agonist. Unfortunately I don't have a very good idea of what that means. My impression is that that means it attenuates certain kinds of seizures, and that a bunch of recreational drugs have been found to have sigma agonist activity, but what does it all mean and how does it fit together? I have no idea.
 
Last edited:
bump....

is this drug actually marketed somewhere? are there other known DXM analogs that exist?
 
hussness said:
Seems to be a sigma agonist. Unfortunately I don't have a very good idea of what that means. ....... a bunch of recreational drugs have been found to have sigma agonist activity, but what does it all mean and how does it fit together? I have no idea.

Yea, I am not clear on this myself. For example, DHEA is a "potent" σ-1 agonist, but lacks recreational potential (although it has mood lifting properties and reduces immobility time in the forced swim).
 
Sigma agonists have been implicated in causing seizures, PCP is a potent sigma agonist, and cocaine also has sigma receptor affinity, haloperidol acts as an antagonist, and has been used for treating cocaine induced seizures.

I read that sigma1 knockout mice display no overt phenotype, which is strange indeed, what is the latest on the function of S1 and S2?

And do we still know of no endogenous ligand?
 
Sigma agonists are cough suppressants and some of them seem to be dissociatives at high doses, but I'm not sure whether kappa or NMDA activity has been ruled out.
 
Known activities of Dimemorfan (in parentheses the values of haloperidol, for comparison):

- sigma-receptors:
......sigma1: Ki = 151 +/- 17 nM (13 +/- 4)
......sigma2: Ki = 4421 +/- 227 nM (148 +/- 31)

- PCP-receptor:
Ki = 16978 +/- 488 nM (63951 +/- 3858 )
...from one of the 2 refs that Hussness posted. Please note that Dimemorfan is a sigma-agonist, while haloperidal acts as antagonist!


Also:

"Anti-inflammatory effects of dimemorfan on inflammatory cells and LPS-induced endotoxin shock in mice."
Wang, Y.-H.; Shen, Y.-C.; Liao, J.-F.; Li, C.-H.; Chou, C.-Y.; Liou, K.-T.; Chou, Y.-C.
British Journal of Pharmacology 2008, 154(6), p.1327

Abstract

Dimemorfan (a sigma1 receptor agonist) showed neuroprotective properties in animal models of inflammation-mediated neurodegenerative conditions, but its effects on inflammatory cells and systemic inflammation remain unclear. The effects of dimemorfan on phorbol-12-myristate-13-acetate (PMA)- and N-formyl-methionyl-leucyl-phenylalanine (fMLP)- induced neutrophils and lipopolysaccharide (LPS)-activated microglial cells, as well as LPS-induced endotoxin shock in mice were elucidated. Dimemorfan decreased PMA- and fMLP-induced prodn. of reactive oxygen species (ROS) and CD11b expression in neutrophils, through mechanisms independent of s1 receptors, possibly by blocking ROS prodn. and G-protein-mediated intracellular calcium increase. Dimemorfan also inhibited LPS-induced ROS and nitric oxide (NO) prodn., as well as that of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha (TNF-a), by inhibition of NADPH oxidase (NOX) activity and suppression of iNOS up-regulation through interfering with nuclear factor kappa-B (NF-kB) signaling in microglial cells. Treatment in vivo with dimemorfan (1 and 5 mg kg-1, i.p., at three successive times after LPS) decreased plasma TNF-a, and neutrophil infiltration and oxidative stress in the lung and liver. Our results suggest that dimemorfan acts via s1 receptor-independent mechanisms to modulate intracellular calcium increase, NOX activity, and NF-kB signaling, resulting in inhibition of iNOS expression and NO prodn., and prodn. of pro-inflammatory cytokines. These effects may contribute its anti-inflammatory action and protective effects against endotoxin shock in mice.


NMDA-receptor-activity can be excluded:

"Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan."
Chou, Yueh-Ching; Liao, Jyh-Fei; Chang, Wan-Ya; Lin, Ming-Fang; Chen, Chieh-Fu.
Brain Research 1999, 821(2), p.516

Abstract

Dextromethorphan ((+)-3-methoxy-N-methylmorphinan, DM) has been shown to have both anticonvulsant and neuroprotective effects. The mechanisms of these CNS effects of DM have been suggested to be assocd. with the low-affinity, noncompetitive, N-methyl-d-aspartate (NMDA) antagonism of DM and/or the high-affinity DM/sigma receptors. DM is largely O-demethylated into the phencyclidine (PCP)-like compd. dextrorphan (DR), which may limit its therapeutic use by producing PCP-like adverse effects, such as hyperlocomotion. Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 yr, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examd. the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. The authors found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, resp.) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 mM). Only DR exhibited moderate affinity for PCP sites (Ki=0.9 mM), whereas DF (Ki=17 mM) and DM (Ki=7 mM) were much less active. DF, DM and DR produced prominent anticonvulsant effects in mice as measured by the supramaximal electroshock test with comparable potency (ED50.apprx.70 mmol/kg, i.p.). At the tested doses (20-260 mmol/kg, i.p.), DM and DR exhibited biphasic effects on the locomotor activity whereas DF produced a consistent dose-dependent decrease. These results revealed that, unlike DM and DR, DF did not cause a PCP-like hyperlocomotion adverse effect that is parallel with the PCP sites binding data. Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to sigma-1 receptors, the very low affinity of DF at PCP sites may suggest that acting on the PCP sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.
With the history of safety and relative less adverse effects, DF appears to be worth further studying on its CNS effects other than the antitussive effect.


And a last one:

"Effects of dextrorotatory morphinans on a3b4 nicotinic acetylcholine receptors expressed in Xenopus oocytes."
Lee, Jun-Ho et al.
European Journal of Pharmacology 2006, 536(1-2), p.85-92

Abstract

We previously demonstrated that dextromethorphan (DM; 3-methoxy-17-methylmorphinan) analogs have neuroprotective effects, and a recent report showed that DM reduces the adverse effects of morphine and blocks a3b4 nicotinic acetylcholine receptors, a major target of anti-addictive agents. Here, we investigated the effects of DM, three of its analogs (DF, 3-methyl-17-methylmorphinan; AM, 3-allyloxy-17-methoxymorphian; and CM, 3-cyclopropyl-17-methoxymorphinan) and one of its metabolites (HM; 3-methoxymorphinan), on neuronal a3b4 nicotinic acetylcholine receptor channel activity expressed in Xenopus laevis oocytes, using the two-microelectrode voltage clamp technique. We found that intraoocyte injection of neuronal a3 and b4 nicotinic acetylcholine receptor subunit cRNAs elicited an inward current (I ACh) in the presence of acetylcholine. Co-treatment with DM, DF, AM, CM or HM inhibited I ACh in a dose-dependent, voltage-independent and reversible manner. The IC50 values for DM, DF, AM, CM and HM were 19.5 ± 5.2, 15.8 ± 4.5, 16.3 ± 1.7, 10.1±2.8, and 13.5 ± 4.0 mM, resp. The order of potency for the inhibition of IACh was CM > HM > DF = AM > DM in oocytes expressing a3b4 nicotinic acetylcholine receptors. The inhibitions of (I ACh) by DM, DF and HM, AM and CM were non-competitive. These results indicate that AM, CM and HM could be novel non-competitive agents regulating a3b4 nicotinic acetylcholine receptor channel activity.

Peace! Murphy
 
Top